Articles
Spin-out biotechs: bridging the gap between academia and pharma

Spin-out biotechs: bridging the gap between academia and pha...

Dr Rich Ferrie discusses the partnerships between academia and pharma, and shares his thoughts on some of the main issues that can arise. The Big Pharma R&D model is broken, and increasingly, the large monoliths are laying off research staff and looking to...

Articles
KOL perspectives: Professor Peter Fitzgerald

KOL perspectives: Professor Peter Fitzgerald

In this interview we speak with KOL Professor Peter Fitzgerald of Stanford University School of Medicine Health Sciences on his thoughts on a successful industry / KOL relationship in the cardiovascular technology landscape. In this new series we seek to hear KOL’s perspectives on how they think they could best work with the pharma industry...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D